Press Release
30 May 2017
Immunicum AB (publ) Announces Participation at Conferences in June
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, has been invited to present the Company at several upcoming conferences in June and t o participate on a panel titled "New Frontiers in Oncology". In addition, the Company will attend the 2017 BIO International Convention.
Sachs Associates 3rd Annual Immuno-Oncology BD&L and Investment Forum Date: June 2, 2017 Presentation Time: 11:10 am Central Standard Time Venue: Hyatt Centric Chicago Magnificent Mile Hotel, Chicago, Illinois
Labiotech Refresh Date: June 8, 2017 Panel: "New Frontiers in Oncology" 10:30 am Central European Time Venue: Spreewerkstätten, Berlin, Germany
Småbolagsdagen Date: June 12, 2017 Presentation Time: 9:20 - 9:50 am Central European Time Venue: Sheraton Hotel Stockholm, Stockholm, Sweden For those who can't participate, the presentation from Småbolagsdagen will be available afterwards on Immunicum's website and will also be broadcasted live on www.smabolagsdagen.net
2017 BIO International Convention (attendance only) Date: June 19-22, 2017 Venue: San Diego Convention Center, San Diego, California
For more information, please contact:
Carlos de Sousa, VD, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com
Investor Relations Sweden
Helena Stångberg Hallvarsson & Halvarsson Telephone: + 46 709 71 12 53 E-mail: helena.stangberg@halvarsson.se
Investor and Media Relations EU/US
MacDougall Biomedical Communications Gretchen Schweitzer or Stephanie May Telephone: +49 89 2424 3494 or +49 175 5711562 E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com
The Company's Certified Adviser is Redeye AB Telephone: +46 (0) 8 545 013 31 www.redeye.se
| About Immunicum AB (publ) Immunicum AB (First North Premier: IMMU.ST) is a clinical stage Company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com |